EP1558630A2 - Neue fluororocarbonierte amphiphile molekulare vektoren zur biomedizinischen und medizinischen verwendung - Google Patents
Neue fluororocarbonierte amphiphile molekulare vektoren zur biomedizinischen und medizinischen verwendungInfo
- Publication number
- EP1558630A2 EP1558630A2 EP03782534A EP03782534A EP1558630A2 EP 1558630 A2 EP1558630 A2 EP 1558630A2 EP 03782534 A EP03782534 A EP 03782534A EP 03782534 A EP03782534 A EP 03782534A EP 1558630 A2 EP1558630 A2 EP 1558630A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- chosen
- compound according
- chain
- formula
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0214077 | 2002-11-08 | ||
FR0214077A FR2846969A1 (fr) | 2002-11-08 | 2002-11-08 | Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical |
PCT/FR2003/003336 WO2004043993A2 (fr) | 2002-11-08 | 2003-11-07 | Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1558630A2 true EP1558630A2 (de) | 2005-08-03 |
Family
ID=32116516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03782534A Withdrawn EP1558630A2 (de) | 2002-11-08 | 2003-11-07 | Neue fluororocarbonierte amphiphile molekulare vektoren zur biomedizinischen und medizinischen verwendung |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060167223A1 (de) |
EP (1) | EP1558630A2 (de) |
JP (1) | JP2006520741A (de) |
AU (1) | AU2003290170A1 (de) |
FR (1) | FR2846969A1 (de) |
WO (1) | WO2004043993A2 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050182060A1 (en) * | 2004-02-13 | 2005-08-18 | Kelly Michael G. | 2-Substituted and 4-substituted aryl nitrone compounds |
GB0408164D0 (en) * | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
FR2883563B1 (fr) * | 2005-03-24 | 2007-06-01 | Ts Pharma Sarl | Nouveaux vecteurs cationiques bolaformes hemifluorocarbones et leurs applications |
CN103764169B (zh) * | 2011-03-31 | 2017-06-13 | 康斯坦策·沙费尔 | 用于非病毒转移核酸的全氟化化合物 |
US11318206B2 (en) | 2014-03-28 | 2022-05-03 | Aposense Ltd | Compounds and methods for trans-membrane delivery of molecules |
AU2015237746B2 (en) * | 2014-03-28 | 2020-01-30 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
US9993563B2 (en) | 2014-03-28 | 2018-06-12 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
US9889202B2 (en) | 2014-03-28 | 2018-02-13 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
CN107257800B (zh) | 2014-12-23 | 2020-06-30 | 达纳-法伯癌症研究所股份有限公司 | 通过双功能分子诱导靶蛋白降解的方法 |
US11230710B2 (en) | 2017-01-09 | 2022-01-25 | Aposense Ltd | Compounds and methods for trans-membrane delivery of molecules |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT8820888A0 (it) * | 1988-06-08 | 1988-06-08 | Eniricerche Spa | Peptidi di sintesi immunologicamente attivi per lapreparazione di vaccini antimalarici. |
GB9019558D0 (en) * | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
FR2694559B1 (fr) * | 1992-08-06 | 1994-10-28 | Atta | Nouveaux dérivés amphiphiles d'aminoacides ou de peptides, leur procédé de préparation et leur utilisation dans des préparations à usage biomédical. |
DE69939689D1 (de) * | 1998-03-19 | 2008-11-20 | Vertex Pharma | Caspase inhibitoren |
-
2002
- 2002-11-08 FR FR0214077A patent/FR2846969A1/fr not_active Withdrawn
-
2003
- 2003-11-07 AU AU2003290170A patent/AU2003290170A1/en not_active Abandoned
- 2003-11-07 EP EP03782534A patent/EP1558630A2/de not_active Withdrawn
- 2003-11-07 JP JP2004550759A patent/JP2006520741A/ja not_active Ceased
- 2003-11-07 WO PCT/FR2003/003336 patent/WO2004043993A2/fr not_active Application Discontinuation
- 2003-11-07 US US10/533,983 patent/US20060167223A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2004043993A2 * |
Also Published As
Publication number | Publication date |
---|---|
AU2003290170A1 (en) | 2004-06-03 |
FR2846969A1 (fr) | 2004-05-14 |
AU2003290170A8 (en) | 2004-06-03 |
JP2006520741A (ja) | 2006-09-14 |
US20060167223A1 (en) | 2006-07-27 |
WO2004043993A3 (fr) | 2004-07-29 |
WO2004043993A2 (fr) | 2004-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2219678B1 (de) | Nanopartikel von wirkstoffen geringer wasserlöslichkeit | |
WO2003064458A2 (fr) | Derives peptidiques, leur preparation et leur application therapeutique et cosmetique | |
WO2004043993A2 (fr) | Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical | |
FR2900656A1 (fr) | Composes c-glycopeptides gem-difluores, leur preparation et leur utilisation notamment pour la preservation de materiaux biologiques | |
EP0037388B1 (de) | Pharmazeutische Stoffe, deren Herstellung und Präparate in denen diese enthalten sind | |
EP1379547B1 (de) | Modifiziertes, als medikamentvorstufe anwendbares cyclosporin und dessen verwendung | |
CA2318512C (fr) | Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications | |
EP1315739B1 (de) | Verfahren zur kupplung in lösung zwischen einem peptid und einer lipophilen verbindung, und verwendungen davon | |
WO1988000594A1 (fr) | Tetrapeptide inhibiteur de l'entree en cycle des cellules souches hematopoietiques, procedes pour son obtention et ses applications | |
EP3416730B1 (de) | Dermatologische kosmetische zusammensetzung mit einem sdkp-peptid oder einem analogon davon | |
JP4747364B2 (ja) | 紫外線皮膚炎抑止剤およびアトピー性皮膚炎抑止剤 | |
EP1999138A1 (de) | Neue amphiphile derivate von alpha-c-phenyl-n-tert.-butylnitron | |
FR2830016A1 (fr) | Compositions pour la vectorisation de derives taxoides a travers la barriere hematoencephalique et leur utilisation pour le traitement des cancers, plus particulierement des cancers du cerveau | |
CA2388663A1 (fr) | Utilisation des acides quinique, shikimique et de leurs derives pour la preparation de ligands du recepteur du mannose | |
WO2003000208A1 (fr) | Composition a usage topique comprenant un produit cytotoxique | |
EP2825531B1 (de) | Vitamin c konjugate | |
WO2014111639A1 (fr) | Derives amphiphiles de composes tr1azamacrocycles, produits et compositions les comprenant, leurs procedes de synthese et leurs utilisations | |
EP0363275A1 (de) | Vektoren mit niedrigem Molekulargewicht, spezifisch gegen Zuckerrezeptoren, ihre Konjugate und Verfahren zu ihrer Herstellung | |
EP2459229B1 (de) | Verwendung von mimetischen oligomeren mit eingeschränkten dipeptiden und tripeptiden als vektorisierer | |
FR2976944A1 (fr) | Prodrogues peptidiques | |
EP2414382A2 (de) | Neue proteasomaktivierende aufhellende peptide und zusammensetzungen, die diese enthalten | |
JPH03106896A (ja) | 30位置換グリチルリチン誘導体及びそれを膜形成成分とするリポソーム製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050531 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20060824 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070104 |